The implications of pharmacogenomics in oncology

The implications of pharmacogenomics in oncology

Bibliographic Details
Main Author:	Jean J. Latimer
Format:	Article
Language:	English
Published:	Tabriz University of Medical Sciences 2023-05-01
Series:	BioImpacts
Online Access:	https://bi.tbzmed.ac.ir/PDF/bi-13-181.pdf

Similar Items

Pharmacogenomic tests in Oncology - finding the right dose
by: Jeziel Basso, et al.
Published: (2021-10-01)

Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.
by: Clint Mizzi, et al.
Published: (2017-01-01)

Oncology and Pharmacogenomics Insights in Polycystic Ovary Syndrome: An Integrative Analysis
by: Verónica Yumiceba, et al.
Published: (2020-10-01)

Pharmacogenomic tests of oncology drugs at Instituto Nacional de Câncer (INCA)
by: Guilherme Suarez-Kurtz
Published: (2021-10-01)

Investigation of community pharmacists’ knowledge and attitudes of pharmacogenomics testing: implication for improved pharmacogenomic testing practice
by: Azza Ramadan, et al.
Published: (2024-01-01)

Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing
by: Alexandre Vivot, et al.
Published: (2017-07-01)

A systematic review of knowledge, attitude and practice of pharmacogenomics in pediatric oncology patients
by: Claire Moore, et al.
Published: (2023-12-01)

Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics
by: Apostolos Papachristos, et al.
Published: (2023-06-01)

Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted
by: Tristan M. Sissung, et al.
Published: (2022-02-01)

Extracellular Vesicles: A Novel Tool Facilitating Personalized Medicine and Pharmacogenomics in Oncology
by: Katja Goričar, et al.
Published: (2021-04-01)

Pharmacogenomics /
by: Kalow, Werner, et al.
Published: (2005)

The Status Quo of Pharmacogenomics of Tyrosine Kinase Inhibitors in Precision Oncology: A Bibliometric Analysis of the Literature
by: Abdallah Alzoubi, et al.
Published: (2024-01-01)

Communication of Pharmacogenomic test results and treatment plans in pediatric oncology: deliberative stakeholder consultations with parents
by: Cristina Longo, et al.
Published: (2021-01-01)

Pharmacogenomics of cutaneous adverse drug reactions as implication for precision medicine
by: Chun-Bing Chen
Published: (2023-01-01)

Epigenetics of Aging and Alzheimer’s Disease: Implications for Pharmacogenomics and Drug Response
by: Ramón Cacabelos, et al.
Published: (2015-12-01)

Pharmacogenomics of Antibiotics
by: Gabriele Stocco, et al.
Published: (2020-08-01)

Pharmacogenomics of Cardiovascular Pharmacology: Pharmacogenomic Network of Cardiovascular Disease Models
by: Toshio Tanaka, et al.
Published: (2008-01-01)

The fallacy of racial pharmacogenomics
by: S.D.J. Pena
Published: (2011-04-01)

The fallacy of racial pharmacogenomics
by: S.D.J. Pena
Published: (2011-04-01)

Healthcare professionals' and consumers' knowledge, attitudes, perspectives, and education needs in oncology pharmacogenomics: A systematic review
by: Chiao Xin Lim, et al.
Published: (2023-12-01)

Pharmacogenomics as a Tool to Limit Acute and Long-Term Adverse Effects of Chemotherapeutics: An Update in Pediatric Oncology
by: Emma C. Bernsen, et al.
Published: (2020-08-01)

Pharmacogenomic Testing to Guide Personalized Cancer Medicine Decisions in Private Oncology Practice: A Case Study
by: George Astras, et al.
Published: (2020-04-01)

Pharmacogenomics in clinical therapeutics /
by: Langman, Loralie J. 536145, et al.
Published: (2012)

The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent
by: Hector Clarke, et al.
Published: (2009-09-01)

6th Golden Helix Pharmacogenomics Day: pharmacogenomics and individualized therapy
by: Stojiljkovic Maja, et al.
Published: (2012-09-01)

Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing
by: Amy J. Turner, et al.
Published: (2024-01-01)

Web Resources for Pharmacogenomics
by: Guoqing Zhang, et al.
Published: (2015-02-01)

Pharmacogenomics in Psychiatric Disorders
by: Roxana-Georgiana Tauser
Published: (2020-06-01)

Pharmacogenomics and Personalized Medicine
by: Erika Cecchin, et al.
Published: (2020-06-01)

Pharmacogenomics of Hypertension Treatment
by: Jacek Rysz, et al.
Published: (2020-07-01)

Pharmacogenomics of hyaluronic acid
by: Elena E. Vaiman, et al.
Published: (2021-07-01)

Clinical use of pharmacogenomics
by: Telenti Amalio
Published: (2012-05-01)

Pharmacogenomics: what is next?
by: Julia edi Iulio, et al.
Published: (2012-01-01)

Editorial: NSAIDs Pharmacogenomics
by: José A. G. Agúndez, et al.
Published: (2021-11-01)

Pharmacogenomics and Rheumatological Practice
by: Chuanhui Xu, et al.
Published: (2021-12-01)

Pharmacogenomics of neuropathic pain
by: Vandana Sharma
Published: (2017-01-01)

Principles of pharmacogenetics and pharmacogenomics /
by: Altman, Russ B. 205766, et al.
Published: (2012)

Pharmacogenomics : methods and applications /
by: 247902 Innocenti, Federico
Published: (2005)

Statistical and computational pharmacogenomics /
by: 385533 Wu, Rongling, et al.
Published: (2009)

Pharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health Transition
by: Nicholas E. Thomford, et al.
Published: (2015-09-01)